CME Accreditation
CONTINUING MEDICAL EDUCATION (CME) ACCREDITATION
The main goals of the 2024 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting are to serve as a primary source of continuing medical education, advance neuroscience research and promote a climate conducive to excellence in clinical practice. The 2024 Annual Scientific Meeting Committee is dedicated to meeting these goals.
The 2024 Annual Meeting is the ultimate resource for the transfer of scientific, technical and intellectual information to the neurosurgical community. Feedback obtained from the online attendee evaluation survey is critical when determining program content. Special recognition is extended to the individuals of the Annual Meeting Committee and Scientific Program Subcommittee and the committees they represent for their perseverance and commitment to making the meeting a success.
LEARNING OBJECTIVES
After attending the 2024 Annual Meeting, participants will be able to:
- Apply advanced techniques for treatments within their sub-specialties.
- Describe complication avoidance in the treatment of diseases to their peers.
- Recognize techniques used in surgical treatments for improved outcomes and complication avoidance.
Identify ways to advocate for patients and practices in the ever-changing healthcare field.
ACCREDITATION AND DESIGNATION
The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AANS designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support Acknowledgement
AANS would like to thank BK Medical for an educational grant to support the AANS2024 Annual Meeting.
This CME activity is supported by in-kind donations from Stryker, BK Medical, Brainlab, UpSurgeon, Karl Storz, ACE Medical, Synaptive, Medtronic, and KLS Martin.
DISCLOSURES
ACCME Standards for Integrity and Independence requires that anyone in a position to control the content of this or any CME activity has disclosed all of his or her financial relationships with any ineligible entity. The ACCME defines an “ineligible entity” as an entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The AANS adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including chairs, planners, staff, presenters, including oral abstract presenters, or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated before the activity begins.
Click Here: Conflict of Interest Disclosure Index (PDF) for all speaker disclosure information.
DISCLAIMER
The material presented at the 2024 AANS Annual Scientific Meeting has been made available by AANS for educational purposes only. The material is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather it is intended to present an approach, view, statement or opinion of the faculty, which may be helpful to others who face similar situations.
Neither the content (whether written or oral) of any course, seminar or other presentation in the program, nor the use of a specific product in conjunction therewith, nor the exhibition of any materials by any parties coincident with the program should be construed as indicating endorsement or approval of the views presented, the products used or the material exhibited by the AANS or its committees, commissions or affiliates.
The AANS makes no statements, representations or warranties (whether written or oral) regarding the Food and Drug Administration (FDA) status of any product used or referred to in conjunction with any course, seminar or other presentation being made available as part of the 2024 Annual Meeting. Faculty members shall have sole responsibility to inform attendees of the FDA status of each product that is used in conjunction with any course, seminar or presentation and whether such use of the product is in compliance with FDA regulations.
The AANS disclaims any and all liability for injury or damages to any individual attending the 2024 Annual Meeting and for all claims that may arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by physicians or any other person. There may be, on occasion, changes in faculty and program content. The AANS is not responsible for expenses incurred by an individual who is not confirmed and for whom space is not available at the meeting. Costs incurred by the registrant, such as airline or hotel fees or penalties, are the responsibility of the registrant.
